MedPath

A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study mechanisms of blood pressure lowering of losartan, Moxonidine and Low sodium diet in former pre-eclamptic wome

Not yet recruiting
Conditions
Preeclampsia
Registration Number
NL-OMON28431
Lead Sponsor
niversity Medical Center Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1.Patient is a female between 18 and 45 years of age on the day of signing informed consent.

2.Have a recent history of preeclampsia that is defined as gestational hypertension and concomitant proteinuria in the second half of pregnancy. Gestational hypertension was defined according to the criteria of the International Society for the Study of Hypertension in Pregnancy (ISSHP) as diastolic blood pressure above 90 mmHg and/or systolic blood pressure above 140 mmHg, measured on two or more separate occasions at least 4 hours apart. Proteinuria was diagnosed with urinary protein was above 300 mg per 24 hour or above 2+ at dipstick urinalysis 17

Exclusion Criteria

1.SBP > 180 mmHg and/or DBP > 110 mmHg during one or more screening measurements.

2.Current pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
mean 24-hour SBP/DBP, mean day/night time SBP/DBP
Secondary Outcome Measures
NameTimeMethod
mean intrapersonal changes in endothelial function (FMD), serum lipid concentrations, HOMA, central blood pressure (PWA), serum and urine concentrations of markers of oxidative stress, serum concentrations of markers of systemic inflammation, arterial stiffness (PWV, PWA), RAAS-hormone concentrations, HRV, 24hr urine measurements
© Copyright 2025. All Rights Reserved by MedPath